Bivalirudin vs Heparin in Patients Who Undergo Transcatheter Aortic Valve Implantation

• Published in: Canadian journal of cardiology 2015-08, Vol.31 (8), p.998-1003
• Main Authors: Lange, Philipp, MD, Greif, Martin, MD, Bongiovanni, Dario, MD, Thaumann, Antonia, Näbauer, Michael, MD, Bischoff, Bernhard, MD, Helbig, Susanne, Becker, Christoph, MD, Schmitz, Christoph, MD, D'Anastasi, Melvin, MD, Mehilli, Julinda, MD, Boekstegers, Peter, MD, Massberg, Steffen, MD, Kupatt, Christian, MD
• Format: Article
• Language: English
• Subjects: Aged, 80 and over; Anticoagulants - therapeutic use; Antithrombins - therapeutic use; Aortic Valve Stenosis - surgery; Cardiovascular; Female; Follow-Up Studies; Heparin - therapeutic use; Hirudins; Humans; Male; Peptide Fragments - therapeutic use; Recombinant Proteins - therapeutic use; Retrospective Studies; Thrombosis - prevention & control; Transcatheter Aortic Valve Replacement; Treatment Outcome
• ISSN: 0828-282X; 1916-7075
• DOI: 10.1016/j.cjca.2015.02.029

Abstract Background We aimed to compare safety and efficacy of the direct thrombin inhibitor bivalirudin with unfractionated heparin (UFH) during transcatheter aortic valve implantation (TAVI). Methods In this retrospective analysis, 461 patients underwent TAVI between 2007 and 2012; 339 patients received bivalirudin, and 122 patients received UFH. In the bivalirudin group, the Sapien XT valve was implanted in 159 (46.9%) patients, and 180 (53.1%) received a Medtronic CoreValve. In the UFH group, only the Medtronic CoreValve was implanted. The primary outcome of interest was the incidence of any bleeding. Secondary outcomes of interest were all-cause mortality and cardiovascular mortality at 72 hours after the procedure and at 30 days. Results No significant difference between the groups was observed for life-threatening bleeding (2.4% for bivalirudin vs 3.3% for UFH; P  = 0.59), major bleeding (8.3% vs 8.2%, respectively; P  = 0.98) and minor bleeding (8.3% vs 7.4%, respectively; P  = 0.76). At 72 hours after the procedure, all-cause mortality was 3.0% in the bivalirudin group and 3.3% for the UFH group ( P  = 0.88), whereas cardiovascular mortality was 3.0% in the bivalirudin group and 2.5% in the heparin group ( P  = 0.77). At 30 days, all-cause mortality was 5.3% vs 4.1% in the bivalirudin and heparin groups ( P  = 0.57) and cardiovascular mortality was 4.4% vs 2.5% ( P  = 0.33). Device success (Valve Academic Research Consortium 2 composite end point) was 94.0% in the bivalirudin-treated and 92.6% in the UFH-treated patients ( P  = 0.60). The early safety at 30 days was 85.3% in the bivalirudin-treated group compared with 83.6% in the UFH-treated group ( P  = 0.65). Conclusions Bivalirudin has a safety and efficacy profile similar to weight-adjusted UFH during the TAVI procedure.